Submitted by Anonymous (not verified) on 7 October 2024 - 10:40
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0391/2023
Source: